Rituximab for people with multiple sclerosis-Reference-Cited by-同舟云学术

Rituximab for people with multiple sclerosis

Published:2021-11-08 Issue:11 Volume:2021 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Filippini Graziella¹,Kruja Jera²,Del Giovane Cinzia³⁴

Affiliation:

1. Scientific Director's Office; Carlo Besta Foundation and Neurological Institute; Milan Italy

2. Neurology; UHC Mother Theresa, University of Medicine; Tirana Albania

3. Institute of Primary Health Care (BIHAM); University of Bern; Bern Switzerland

4. Population Health Laboratory (#PopHealthLab); University of Fribourg; Fribourg Switzerland

Publisher

Wiley

Subject

Pharmacology (medical)

Reference220 articles.

1. Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing-remitting multiple sclerosis is effective and safe;Alcalá;Journal of Neurology,2019

2. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients;Alping;Annals of Neurology,2016

3. Cancer risk for fingolimod, natalizumab, and rituximab in multiple sclerosis patients;Alping;Annals of Neurology,2020

4. Cancer risk among Swedish multiple sclerosis patients: a nationwide cohort study comparing rituximab, fingolimod and natalizumab;Alping;Multiple Sclerosis Journal,2018

5. Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis;Boremalm;European Journal of Neurology,2019

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Disease modifying treatment guidelines for multiple sclerosis in the United Arab Emirates;Multiple Sclerosis and Related Disorders;2024-08

2. Thách thức trong chẩn đoán và điều trị xơ cứng rải rác khởi phát rất muộn: ca lâm sàng;Tạp chí thần kinh học Việt Nam;2024-04-16

3. Cancer and multiple sclerosis: 2023 recommendations from the French Multiple Sclerosis Society;Multiple Sclerosis Journal;2024-02-15

4. Anti-CD20 antibodies in relapsing multiple sclerosis: Protocol for a systematic review and network meta-analysis;2024-01-15

5. Rituximab for the treatment of relapsing-remitting multiple sclerosis in Thailand: an economic evaluation and budget impact analysis;BMC Health Services Research;2023-10-13